$4.25
0.47% yesterday
NYSE, Sep 27, 10:00 pm CET
ISIN
US68218J1034
Symbol
OABI
Sector
Industry

OmniAb Stock price

$4.25
-0.06 1.39% 1M
-1.14 21.15% 6M
-1.92 31.12% YTD
-0.92 17.80% 1Y
-4.54 51.65% 3Y
-4.54 51.65% 5Y
-4.54 51.65% 10Y
NYSE, Closing price Fri, Sep 27 2024
+0.02 0.47%
ISIN
US68218J1034
Symbol
OABI
Sector
Industry

Key metrics

Market capitalization $495.44m
Enterprise Value $462.54m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 21.31
P/S ratio (TTM) P/S ratio 22.82
P/B ratio (TTM) P/B ratio 1.70
Revenue growth (TTM) Revenue growth -63.33%
Revenue (TTM) Revenue $21.71m
EBIT (operating result TTM) EBIT $-82.85m
Free Cash Flow (TTM) Free Cash Flow $-46.81m
Cash position $57.23m
EPS (TTM) EPS $-0.62
P/E forward negative
P/S forward 15.91
EV/Sales forward 14.85
Short interest 9.17%
Show more

Is OmniAb a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.

OmniAb Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a OmniAb forecast:

8x Buy
100%

Analyst Opinions

8 Analysts have issued a OmniAb forecast:

Buy
100%

Financial data from OmniAb

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
22 22
-
100%
- Direct Costs 21 21
-
96%
0.89 0.89
-
4%
- Selling and Administrative Expenses 5.79 5.79
-
27%
- Research and Development Expense 57 57
-
263%
-62 -62
-
-286%
- Depreciation and Amortization 21 21
-
96%
EBIT (Operating Income) EBIT -83 -83
-
-382%
Net Profit -62 -62
-
-287%

In millions USD.

Don't miss a Thing! We will send you all news about OmniAb directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

OmniAb Stock News

Neutral
Seeking Alpha
about 2 months ago
OmniAb, Inc. (NASDAQ:OABI ) Q2 2024 Earnings Call August 8, 2024 4:30 PM ET Company Participants Kurt Gustafson - Chief Financial Officer Matt Foehr - President and Chief Executive Officer Conference Call Participants Michael Sonntag - Leerink Partners Chad Wiatrowski - TD Cowen Stephen Willey - Stifel Conor McNamara - RBC Capital Markets Operator Good afternoon and welcome to OmniAb Incorporat...
Positive
Seeking Alpha
about 2 months ago
In the first half of 2024, our long book performed strong relative to the Russell 2000, driven by our high-conviction positions. We are pleased with our relative performance and believe the Russell 2000 remains a more appropriate benchmark for comparison. Top gainers include FTAI Aviation and FTAI Infrastructure, while top detractors include Latch and Industrial Short.
Neutral
Business Wire
4 months ago
EMERYVILLE, Calif.--(BUSINESS WIRE)--OmniAb, Inc. (NASDAQ: OABI) today announced the publication of a peer-reviewed paper titled “Chickens with a Truncated Light Chain Transgene Express Single-Domain H Chain-Only Antibodies” in the Journal of Immunology demonstrating that chickens can be genetically engineered to produce functional heavy chain-only single-domain antibodies. sdAbs are produced n...
More OmniAb News

Company Profile

OmniAb, Inc. operates as a drug discovery company. It focuses on developing human monoclonal and bispecific therapeutic antibodies. Its platform includes the biological intelligence of its transgenic animals, including OmniRat, OmniChicken and OmniMouse. The company was founded on December 14, 2015 and is headquartered in Emeryville, CA.

Head office United States
CEO Matthew Foehr
Employees 106
Founded 2015
Website www.omniab.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today